Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention

被引:0
|
作者
Thuraiaiyah, Jani [1 ]
Philbert, Berit Thornvig [1 ]
Jensen, Annette Schophuus [1 ]
Xing, Lucas Yixi [1 ]
Joergensen, Troels Hoejsgaard [1 ]
Lim, Chee Woon [1 ]
Jakobsen, Frederikke Noerregaard [2 ]
Baekke, Pernille Steen [1 ]
Schmidt, Michael Rahbek [1 ]
Idorn, Lars [3 ]
Holdgaard Smerup, Morten [4 ]
Johansen, Jens Brock [2 ]
Riahi, Sam [5 ,6 ]
Nielsen, Jens Cosedis [7 ,8 ]
De Backer, Ole [1 ]
Sondergaard, Lars [9 ]
Jons, Christian [1 ]
机构
[1] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Inge Lehmanns Vej 7, DK-2100 Copenhagen, Denmark
[2] Odense Univ Hosp, Dept Cardiol, Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Paediat, Rigshosp, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Cardiothorac Surg, Rigshosp, Copenhagen, Denmark
[5] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark
[6] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
[7] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark
[8] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[9] Abbott Struct Heart, Santa Clara, CA USA
来源
EUROPACE | 2024年 / 26卷 / 09期
关键词
Implantable cardioverter defibrillator; Appropriate therapy; Paediatric cardiology; Congenital heart disease; Sudden cardiac death; SUDDEN CARDIAC DEATH; CONGENITAL HEART-DISEASE; LONG QT SYNDROME; CHILDREN; YOUNG; APPROPRIATE; NATIONWIDE; REGISTRY; RISK; MULTICENTER;
D O I
10.1093/europace/euae245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The decisions about placing an ICD in a child are more difficult than in an adult due to longer expected lifespan and the complication risk. Young patients gain the most years from ICDs, despite higher risk of device-related complications. The secondary prevention ICD indication is clear, and device is implanted regardless of potential complications. For primary prevention, risk of sudden cardiac death and complications need to be evaluated. We aimed to compare outcomes for primary and secondary prevention ICDs.Methods and results Retrospective nationwide cohort study including paediatric patients identified from the Danish ICD registry with ICD implanted at an age <= 15 from 1982-21. Demographics, complications (composite of device-related infections or lead-failure requiring re-operation, mortality because of arrhythmia, or unknown cause), and mortality were retrieved from medical charts. Endpoint was appropriate therapy (shock or anti-tachycardia pacing for ventricular tachycardia or fibrillation). Of 72 receiving an ICD, the majority had channelopathies (n = 34) or structural heart diseases (n = 28). ICDs were implanted in 23 patients for primary prevention and 49 for secondary prevention, at median ages of 13.8 and 11.6 years (P-value 0.01), respectively. Median follow-up was 9.0 (interquartile ranges: 4.7-13.5) years. The 10-year cumulative incidence of first appropriate therapy was 70%, with complication and inappropriate therapy rates at 41% and 15%, respectively. No difference was observed between prevention groups for all outcomes. Six patients died during follow-up.Conclusion In children, two-thirds are secondary prevention ICDs. Children have higher appropriate therapy and complication rates than adults, while the inappropriate therapy rate was low. Graphical Abstract
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Comparison of implantable cardioverter-defibrillator therapy in primary vs. secondary prevention of sudden cardiac death in young patients
    Shah, M
    Zeltser, I
    Rossano, J
    Tanel, R
    Rhodes, L
    [J]. CIRCULATION, 2004, 110 (17) : 496 - 496
  • [2] Electrical storms in patients with an implantable cardioverter defibrillator: Primary vs. secondary prophylaxis
    Tint, Diana
    Micu, Sorin
    Petris, Antoniu
    [J]. MOLECULAR CRYSTALS AND LIQUID CRYSTALS, 2016, 628 (01) : 1 - 6
  • [3] Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention
    Reinder Evertz
    Tessa van der Heijden
    Rypko Beukema
    Sjoerd Westra
    Esther Meindersma
    Caroline van Deursen
    Kevin Vernooy
    [J]. Netherlands Heart Journal, 2023, 31 : 348 - 356
  • [4] Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention
    Evertz, Reinder
    van der Heijden, Tessa
    Beukema, Rypko
    Westra, Sjoerd
    Meindersma, Esther
    van Deursen, Caroline
    Vernooy, Kevin
    [J]. NETHERLANDS HEART JOURNAL, 2023, 31 (09) : 348 - 356
  • [5] Syncope in Primary Prevention Implantable Cardioverter Defibrillator Patients
    Goldenberg, Gustavo
    Bental, Tamir
    Kadmon, Udi
    Zabarsky, Ronit
    Kusnick, Jairo
    Barsheshet, Mon
    Golovchiner, Gregory
    Strasberg, Boris
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (06): : 318 - 321
  • [6] Risk factors for first and recurrent ICD therapy in primary and secondary prevention patients with an implantable cardioverter defibrillator
    Frodi, D.
    Diederichsen, S.
    Xing, L. Y.
    Jacobsen, P. K.
    Risum, N.
    Svendsen, J. H.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [7] Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
    Sarrias, Axel
    Galve, Enrique
    Sabate, Xavier
    Moya, Angel
    Anguera, Ignacio
    Nunez, Elaine
    Villuendas, Roger
    Alcalde, Oscar
    Garcia-Dorado, David
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (06): : 492 - 496
  • [8] Implantable cardioverter defibrillator in paediatric patients
    Naegele, Herbert
    [J]. EUROPACE, 2010, 12 (12): : 1659 - 1659
  • [9] The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy
    Zecchin, M
    Di Lenarda, A
    Proclemer, A
    Faganello, G
    Facchin, D
    Petz, E
    Sinagra, G
    [J]. EUROPACE, 2004, 6 (05): : 400 - 406
  • [10] Update on primary prevention implantable cardioverter-defibrillator therapy
    Epstein A.E.
    [J]. Current Cardiology Reports, 2009, 11 (5) : 335 - 342